InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

Description of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

Introduction

InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) is a monoclonal antibody used as a therapeutic target in the treatment of various diseases. This antibody specifically targets the human interferon alpha/beta receptor subunit 1 (IFNAR1), which plays a critical role in the immune response against viral infections and other diseases. In this article, we will discuss the structure, activity, and potential applications of this antibody in both research and therapeutic settings.

Structure of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

The InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) is a monoclonal antibody, meaning it is produced by a single clone of B cells. It is an IgG1 isotype antibody, which is a type of immunoglobulin that is commonly found in the blood and plays a crucial role in the immune response. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL) and one variable domain (VL). The variable domains are responsible for binding to the specific target, IFNAR1, while the constant domains provide stability and effector functions.

Activity of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

The main activity of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) is to block the interaction between IFNAR1 and its ligands, interferon alpha and beta. This prevents the activation of the downstream signaling pathway, leading to a decrease in the immune response. This antibody has been shown to effectively neutralize the activity of IFNAR1 in both in vitro and in vivo studies. It has also been demonstrated to inhibit the production of pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha, which are involved in various inflammatory diseases.

Application of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) as a Therapeutic Target

The therapeutic potential of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) lies in its ability to modulate the immune response. It has been studied as a potential treatment for various autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. By blocking the activity of IFNAR1, this antibody can reduce the production of autoantibodies and the activation of immune cells, leading to a decrease in disease severity.

In addition, InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) has also been investigated as a potential therapy for viral infections. By inhibiting the activity of IFNAR1, this antibody can prevent the virus from evading the immune response and replicating in the host cells. It has shown promising results in preclinical studies against viruses such as hepatitis C, influenza, and HIV.

Research Use of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

Apart from its potential therapeutic applications, InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) is also widely used in research. It is commonly used as a tool to study the role of IFNAR1 in various diseases and to understand the mechanisms of action of this receptor. This antibody has been used in various in vitro and in vivo studies to investigate the signaling pathways activated by IFNAR1 and its role in immune regulation.